News ArchivesRead News

Your Weekly Parkinson's News Update for the Week of 3.11.19

Monday March 11, 2019
Cognitive Behavioral Therapy Effective in
Treating Depression in Patients With Parkinson's
Psychiatry Advisory
"Cognitive behavioral therapy (CBT) was associated with significant improvements in depressive symptoms in patients with Parkinson's, according to study data published in the International Journal of Geriatric Psychiatry. The largest magnitude of benefit of CBT in study participants was observed for cognitive symptoms of depression, for example, sadness, guilt, and rumination."
3D Printed Device Shows Promise for Treating Parkinson’s
3D Printing Media Network
A 3D printed device, created by UK-based metal AM company Renishaw, was recently used in a breakthrough clinical trial, demonstrating the ability to precisely deliver a new drug candidate for treating Parkinson’s. The drug in question, Glial Cell Line Derived Neurotrophic Factor (GDNF), can help to regenerate dying dopamine brain cells in patients, resulting in improved symptoms.
The groundbreaking clinical trial for treating Parkinson’s, conducted by the North Bristol NHS Trust, was recently highlighted in a BBC Two documentary called The Parkinson’s Drug Trial: A Miracle Cure?
Researchers Decode How Cancer Drug Works
in Brains of People with Parkinson's
"In the journal Pharmacology Research & Perspectives, investigators report that a single low dose of the leukemia drug, nilotinib (Tasigna® by Novartis), reduces levels of a toxic protein that prevents the brain from utilizing dopamine that is stored in tiny vesicles, or pockets, in brain areas that may control movement.
The researchers say nilotinib appears to rev up the ability of immune cells within the brain to reduce the constant flow of the misshapen alpha-synuclein protein produced by damaged neurons, allowing normal alpha-synuclein to facilitate release of stored dopamine."
New Strategy Targets Parkinson’s by Improving
Dopamine Metabolism, Study Reports
Parkinson's News Today
In contrast to what was previously believed, a key protein implicated in Parkinson’s  — called Nurr1 — can be modulated using naturally existing molecules or engineered small molecules to restore dopamine production in brain cells, according to a study.
Conducted by researchers from the University of California San Francisco (UCSF), the new study provides evidence that the activation of Nurr1 may represent a viable strategy to slow or halt the progression of Parkinson’s disease.